Abstract
The identification of selective benzodiazepine site ligands, endowed with anxiolytic and anti‐hyperalgesic action, is a relevant opportunity for the treatment of pain syndromes. Previously, we selected a compound with a promising anti‐hyperalgesic profile, the 3‐iodo‐8‐benzylaminopyrazolo [5,1‐c][1,2,4]benzotriazine 5‐oxide. Aimed to verify the structure–activity relationship, the corresponding 7‐arylakylamino derivatives were synthesized. Compounds were tested for their affinity at GABAA‐receptor subtype; the compound 12 was further investigated in animal models of anxiety and persistent pain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
